C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
26 Abril 2024 - 9:44AM
Business Wire
Collaboration Highlights C2N’s Growing Global
Footprint for Offering Blood Biomarker Research Testing That’s
Transforming Clinical Research and Early Diagnosis
C₂N Diagnostics, LLC (“C2N”), a specialty diagnostics company
with a vision to bring Clarity Through Innovation®, today announced
a partnership agreement with Mediford Corporation, a PHC Holdings
Corporation (TSE 6523) Group Company and premier provider of
clinical research to the biopharma industry throughout Japan. The
agreement greatly increases access to C₂N Biopharma Clinical
Research Services, which offers highly sensitive mass
spectrometry-based identification, quantification and monitoring of
proteins, protein fragments (peptides) and other biomolecules
implicated in human neurological diseases and overall brain
health.
The Mediford Corporation alliance means more researchers in
Japan can access C₂N’s Precivity™ line of high-performance blood
tests that aid in the diagnosis, prognosis, staging, and treatment
monitoring of Alzheimer’s disease (AD), including Aβ42/40 and
%p-tau217, and other proprietary biomarkers such as those that
measure the microtubule-binding domain of tau protein (e.g.,
MTBR-tau). The company’s latest innovation in the MTBR-tau
biomarker intends to uniquely detect the presence and burden of
neurofibrillary “tau” tangles (NFTs) comprised of aggregated tau
proteins in the brain and as a potential alternative to invasive,
costly and often inaccessible tau PET tracers.
C₂N’s expertise in treatment monitoring is highlighted by
researchers using its Precivity-Aβ™ blood biomarker in the Clarity
AD clinical trial for lecanemab and its Precivity-p-tau217™ blood
biomarker in the TRAILBLAZER-ALZ 2 clinical trial for donanemab. As
a screening tool to improve the time, efficiency and costs of
clinical trial enrollment, C2N’s blood biomarkers are also being
used in the landmark global AD prevention study of AHEAD 3-45,
involving evaluation of lecanemab safety and efficacy among
individuals at high-risk for future development of clinical AD.
In recognizing wide global interest in its services, C₂N has
appointed Maki Hoshiko, Ph.D., as the lead for its Japan strategy
and scientific collaborations. Hoshiko, who’s based in Kyoto,
Japan, has a well-established background as a neuroscientist
focused on the commercialization aspects of the field. She
previously served in a similar role with Biogen Inc.
Research Indicates Japanese at High Risk for Alzheimer’s
Disease
C₂N’s Japan expansion is occurring as the high-density
population country accounted for the second-highest diagnosed
prevalent cases of Alzheimer's disease (at 26%) compared to
Germany, France, Italy, Spain, the United Kingdom and the United
States, according to the “Alzheimer's disease (AD) - Epidemiology
Forecast - 2032.” The report states that the country has nearly 4
million diagnosed prevalent cases of Alzheimer's disease. Other
research has found that Japan has the highest proportion of people
with dementia of any country.
C2N CEO Dr. Joel Braunstein says, “Japan is a vitally important
country in the Alzheimer’s research sector, as both a leading
technology innovation hub and also a region of the world where
society places a high premium on healthy aging of its citizens. We
believe our partnership with Mediford Corporation will unlock many
opportunities and possibilities. Mediford Corporation is known for
providing clinical and non-clinical analysis that supports each
stage of drug research and development, including advanced
treatment options. We believe this collaboration provides an
excellent pathway to reaching clinical trial researchers and
drugmakers searching for the newest treatment solutions and
products.”
Mediford Corporation President Mr. Kei Shimizu says, “We’ve
closely examined the options for offering blood tests to assess for
Alzheimer’s pathology and concluded that C₂N’s blood biomarker
testing for clinical trial and treatment monitoring delivers one of
the highest standard. C₂N’s assays have been used in over 150
Alzheimer’s disease and other research studies throughout the
United States and the world; this includes globally impactful
treatment and prevention trials involving disease-modifying
therapies that are changing the outlook of Alzheimer’s disease.
C₂N’s excellence in quality stands out for its success in
developing and commercializing novel diagnostics for Alzheimer’s
disease and related forms of neurodegeneration to improve treatment
decisions and patients’ lives.”
For researchers in Japan interested in learning more, please
contact General Affairs and Human Resource Department of Mediford
Corporation at medf-dds-gas@gg.mediford.com.
About C2N Diagnostics, LLC
C₂N is a specialty diagnostics company with a vision to bring
Clarity Through Innovation®. C₂N strives to provide exceptional
clinical laboratory services and advanced diagnostic solutions in
the field of brain health. C₂N’s high-resolution mass
spectrometry-based biomarker services and products are used for:
clinical decision-making to improve patient care, including
diagnosis and treatment monitoring; maximizing the quality and
efficiency of clinical trials that test novel treatments for
neurodegeneration; and providing innovative tools to help
healthcare researchers better understand novel mechanisms of
disease, identify new treatment targets, and conduct important
epidemiologic studies to improve global public health. C₂N assays
have been used in over 150 Alzheimer’s disease and other research
studies throughout the U.S. and the world. This includes landmark
treatment and prevention trials involving disease-modifying
therapies (DMTs) that are changing the trajectory of Alzheimer’s
disease. C₂N has ongoing collaborations with multi-national
pharmaceutical and biotech companies, leading academic
institutions, National Institute on Aging, Alzheimer’s Association,
and other non-profits and consortiums. Over 30,000
Precivity™-related biomarker measures have been reported through
peer-reviewed publications, with many more manuscripts currently
under review.
The company acknowledges generous support from National
Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery
Foundation, BrightFocus Foundation and Alzheimer’s Association. For
more information visit www.C2N.com.
About Mediford Corporation
Mediford Corporation is a Japanese subsidiary of PHC Holdings
Corporation (TSE 6523). It started drug development support
services as the basis business in November 2023 as a member of PHC
Group. Mediford Corporation provides comprehensive services for
drug development from an exploratory phase of R&D to a clinical
development phase. Mediford Corporation strives to enhance its
services for pharmaceutical companies and analytical laboratories
globally through analytical technologies required in both
non-clinical and clinical studies to realize emerging varieties of
treatment modality, through collaboration with
pharmaceutical/biotech companies and academia in advanced
scientific fields. For more information visit www.mediford.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426765375/en/
For C2N Diagnostics
COMPANY CONTACT:
Joni Henderson JHenderson@c2n.com 314-464-0009
MEDIA CONTACT:
Adam Shapiro Adam.Shapiro@ASPR.bz 202-427-3603
For Mediford Corporation
[For product and service inquiries] General Affairs and Human
Resource Department Mediford Corporation Phone: +81-3-6905-5860
E-mail: medf-dds-gas@gg.mediford.com
[For IR and media inquiries] Investor Relations & Corporate
Communications Department PHC Holdings Corporation Phone:
+81-3-6778-5311 E-mail: phc-pr@gg.phchd.com